ClinicalTrials.gg
Active, not recruitingNCT04099251CheckMate76KUpdated Aug 7, 2026Results posted

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

A Phase 3 interventional study of Nivolumab and Placebo in Melanoma, sponsored by Bristol-Myers Squibb. Active, not recruiting at 130 sites in 20 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
790
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 63 under way, 9 of them phase 3. Nivolumab · Melanoma.

Enrollment
7th of 142
790 · median 50
Started
2019
with 15 others
Phase 3
19 of 142
2 open now
Primary completion
2022-06
later than 4 of 62 live
Registered
75th of 142
by date
Lead sponsor
23 of 142
Bristol-Myers Squibb

Among the 142 studies testing nivolumab in Melanoma, this one is the 7th largest by enrollment, is one of 16 that started in 2019, is one of 19 in phase 3, reaches primary completion later than 4 of the 62 other live ones, and was the 75th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies testing nivolumab in Melanoma, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Had a negative sentinel lymph node .
  • Participant has not been previously treated for melanoma.
  • 0 or 1.
  • Participants must have been diagnosed with confirmed, Resected, Stage IIB/C cutaneous melanoma.

Exclusion criteria

Exclusion Criteria:

  • History of ocular or mucosal melanoma.
  • Pregnant or nursing women.
  • Participants with active known or suspected disease.
  • Known history of allergy or to study drug components.
  • Prior treatment with an , anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or agents that target IL-2 pathways, T-cell stimulators, or checkpoint pathways.

Other protocol defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
790 participants (actual)

Study arms

  • Experimental
    Nivolumab

    Biological: Nivolumab

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Recurrence Free Survival (RFS)

    Recurrence Free Survival (RFS) is defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (whatever the cause), whichever occurs first. For participants who remain alive and whose disease has not recurred or did not die, RFS will be censored on the date of last evaluable disease assessment. For those participants who remained alive and had no recorded post-randomization tumor assessment, RFS will be censored on the day of randomization.

    Time frame: From randomization up to the date of first recurrence, new primary melanoma, or death (whatever the cause), whichever occurs first (up to 32 months)

Secondary outcomes

  1. Distant Metastasis-Free Survival (DMFS)

    Investigator-assessed distant metastasis-free survival (DMFS) is defined as the time between the date of randomization and the date of first distant metastasis or date of death (whatever the cause), whichever occurs first. Participants with no baseline disease assessment, no on-study disease assessments and no death, and no distant metastasis and no death will be censored. Participants with no baseline disease assessment and no on-study disease assessments and death are censored on the date of randomization. Participants with no recurrence and no death will be censored on the date of their last evaluable disease assessment.

    Time frame: From randomization up to the date of first distant metastasis or date of death (whatever the cause), whichever occurs first (up to approximately 32 months)

  2. Duration of Treatment on Next Line Therapy Per Investigator Assessment

    Duration of treatment is an investigator-assessed outcome of next-line therapy (NLT) defined as the time from first dose date of NLT to last dose date of NLT. Participants who did not stop the NLT were censored.

    Time frame: From first dose date of next-line therapy to last dose date of next-line therapy (up to approximately 32 months)

  3. Progression-Free Survival Through Next-Line Therapy

    Progression-free survival through next-line therapy (PFS2) is defined as the time from randomization to recurrence/objective disease progression after the start of the next-line of systemic anti-cancer therapy, or to the start of a second next-line systemic therapy, or to death from any cause, whichever occurs first. Participants who did not receive subsequent systemic anti-cancer therapy who died will be considered as having the event on the date of death. Participants who received subsequent systemic anti-cancer therapy who had a disease progression after the start of therapy will be considered as having the event on the date of disease progression. Participants who died or started second next-line therapy, the date of death or start date of second next-line therapy will be the event date, whichever is earlier. Participants who did not experience disease progression, death, or second next-line therapy will be censored on the last known alive date.

    Time frame: From randomization to recurrence/objective disease progression after the start of the next-line therapy, or to the start of a second next-line systemic therapy, or to death from any cause, whichever occurs first (up to approximately 32 months)

  4. Number of Participants Experiencing Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

    Time frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months)

  5. Number of Participants Experiencing Adverse Events Leading to Discontinuation

    An Adverse Event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.

    Time frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months)

  6. Number of Participants Experiencing Select Adverse Events

    The number of participants experiencing all-cause select adverse events (AEs). An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.

    Time frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months)

  7. Number of Participants Experiencing Serious Adverse Events (SAEs)

    A Serious Adverse Events (SAE) is defined as any untoward or unfavorable medical occurrence in a participants that results in death, is life threatening, or places the participant at immediate risk of death from the event as it occurred, requires or prolongs hospitalization, causes persistent or significant disability or incapacity, results in congenital anomalies or birth defects, and is another condition which investigators judge to represent significant hazards.

    Time frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months)

  8. Number of Participants Experiencing Death

    All study participants who died during the blinded phase of the study following treatment.

    Time frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months)

  9. Number of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities in Selected Hematology Parameters

    The number of participants experiencing Grade 3 or 4 laboratory abnormalities in the specific pre-determined hematology tests.

    Time frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months)

  10. Number of Participants Experiencing Laboratory Abnormalities in Selected Liver Parameters

    The number of participants experiencing laboratory abnormalities in the specific pre-determined liver tests.

    Time frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months)

  11. Overall Survival (OS)

    OS is defined as the time between the date of randomization and the date of death. For those without documentation of death, OS will be censored on the last date the participant was known to be alive.

    Time frame: From randomization up to the date of death or the last date the participant was known to be alive

07

Results

Posted Jul 27, 2023

Participant flow

Pre-Treatment
Participant flow — Pre-Treatment
MilestoneNivolumabPlacebo
Started526264
Completed524264
Not completed20
Withdrew: Other reasons10
Withdrew: Participant no longer meets study criteria10
Blinded Treatment Phase
Participant flow — Blinded Treatment Phase
MilestoneNivolumabPlacebo
Started524264
Completed257158
Not completed267106
Withdrew: Other reasons167
Withdrew: Disease recurrence2641
Withdrew: Adverse event unrelated to study drug111
Withdrew: Study drug toxicity947
Withdrew: Participant no longer meets study criteria10
Withdrew: Lost to follow-up10
Withdrew: Death62
Withdrew: Withdrawal by subject187
Withdrew: Participant request to discontinue study treatment290
Withdrew: Ongoing treatment6439
Withdrew: Maximum clinical benefit12
Optional Open-Label Phase Pre-Treatment
Participant flow — Optional Open-Label Phase Pre-Treatment
MilestoneNivolumabPlacebo
Started230
Completed228
Not completed02
Withdrew: Participant withdrew consent after re-baseline visit02
Optional Open-Label Phase Treatment
Participant flow — Optional Open-Label Phase Treatment
MilestoneNivolumabPlacebo
Started228
Completed03
Not completed225
Withdrew: Disease progression/recurrence05
Withdrew: Decision by principal investigator01
Withdrew: Study drug toxicity02
Withdrew: Ongoing treatment217

Outcome measures

PrimaryRecurrence Free Survival (RFS)

Recurrence Free Survival (RFS) is defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (whatever the cause), whichever occurs first. For participants who remain alive and whose disease has not recurred or did not die, RFS will be censored on the date of last evaluable disease assessment. For those participants who remained alive and had no recorded post-randomization tumor assessment, RFS will be censored on the day of randomization.

Time frame:
From randomization up to the date of first recurrence, new primary melanoma, or death (whatever the cause), whichever occurs first (up to 32 months)
Reported as:
Median · Months
Recurrence Free Survival (RFS)
MonthsNivolumabPlacebo
Recurrence Free Survival (RFS)NA (28.52 to NA)NA (21.62 to NA)
Statistical analysis
  • Nivolumab vs Placebo · Regression, Cox · p = < 0.0001 · Hazard ratio (hr): 0.42 · 95% CI 0.30 to 0.59
SecondaryDistant Metastasis-Free Survival (DMFS)

Investigator-assessed distant metastasis-free survival (DMFS) is defined as the time between the date of randomization and the date of first distant metastasis or date of death (whatever the cause), whichever occurs first. Participants with no baseline disease assessment, no on-study disease assessments and no death, and no distant metastasis and no death will be censored. Participants with no baseline disease assessment and no on-study disease assessments and death are censored on the date of randomization. Participants with no recurrence and no death will be censored on the date of their last evaluable disease assessment.

Time frame:
From randomization up to the date of first distant metastasis or date of death (whatever the cause), whichever occurs first (up to approximately 32 months)
Reported as:
Median · Months
Distant Metastasis-Free Survival (DMFS)
MonthsNivolumabPlacebo
Distant Metastasis-Free Survival (DMFS)NA (28.52 to NA)NA (NA to NA)
SecondaryDuration of Treatment on Next Line Therapy Per Investigator Assessment

Duration of treatment is an investigator-assessed outcome of next-line therapy (NLT) defined as the time from first dose date of NLT to last dose date of NLT. Participants who did not stop the NLT were censored.

Time frame:
From first dose date of next-line therapy to last dose date of next-line therapy (up to approximately 32 months)
Reported as:
Median · Months
Duration of Treatment on Next Line Therapy Per Investigator Assessment
MonthsNivolumabPlacebo
Duration of Treatment on Next Line Therapy Per Investigator Assessment4.17 (2.69 to 8.38)11.14 (5.85 to NA)
SecondaryProgression-Free Survival Through Next-Line Therapy

Progression-free survival through next-line therapy (PFS2) is defined as the time from randomization to recurrence/objective disease progression after the start of the next-line of systemic anti-cancer therapy, or to the start of a second next-line systemic therapy, or to death from any cause, whichever occurs first. Participants who did not receive subsequent systemic anti-cancer therapy who died will be considered as having the event on the date of death. Participants who received subsequent systemic anti-cancer therapy who had a disease progression after the start of therapy will be considered as having the event on the date of disease progression. Participants who died or started second next-line therapy, the date of death or start date of second next-line therapy will be the event date, whichever is earlier. Participants who did not experience disease progression, death, or second next-line therapy will be censored on the last known alive date.

Time frame:
From randomization to recurrence/objective disease progression after the start of the next-line therapy, or to the start of a second next-line systemic therapy, or to death from any cause, whichever occurs first (up to approximately 32 months)
Reported as:
Median · Months
Progression-Free Survival Through Next-Line Therapy
MonthsNivolumabPlacebo
Progression-Free Survival Through Next-Line TherapyNA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants Experiencing Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

Time frame:
From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsNivolumabPlacebo
Any Grade502229
Grade 3-411532
SecondaryNumber of Participants Experiencing Adverse Events Leading to Discontinuation

An Adverse Event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.

Time frame:
From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events Leading to Discontinuation
ParticipantsNivolumabPlacebo
Number of Participants Experiencing Adverse Events Leading to Discontinuation919
SecondaryNumber of Participants Experiencing Select Adverse Events

The number of participants experiencing all-cause select adverse events (AEs). An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.

Time frame:
From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Select Adverse Events
ParticipantsNivolumabPlacebo
Endocrine11614
Gastrointestinal12241
Hepatic8635
Pulmonary101
Renal3010
Skin21764
Hypersensitivity/Infusion Reactions332
SecondaryNumber of Participants Experiencing Serious Adverse Events (SAEs)

A Serious Adverse Events (SAE) is defined as any untoward or unfavorable medical occurrence in a participants that results in death, is life threatening, or places the participant at immediate risk of death from the event as it occurred, requires or prolongs hospitalization, causes persistent or significant disability or incapacity, results in congenital anomalies or birth defects, and is another condition which investigators judge to represent significant hazards.

Time frame:
From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Serious Adverse Events (SAEs)
ParticipantsNivolumabPlacebo
Number of Participants Experiencing Serious Adverse Events (SAEs)7429
SecondaryNumber of Participants Experiencing Death

All study participants who died during the blinded phase of the study following treatment.

Time frame:
From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Death
ParticipantsNivolumabPlacebo
Number of Participants Experiencing Death148
SecondaryNumber of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities in Selected Hematology Parameters

The number of participants experiencing Grade 3 or 4 laboratory abnormalities in the specific pre-determined hematology tests.

Time frame:
From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities in Selected Hematology Parameters
ParticipantsNivolumabPlacebo
PLATELET COUNT10
LYMPHOCYTES (ABSOLUTE), LOCAL LAB54
ABSOLUTE NEUTROPHIL COUNT01
SecondaryNumber of Participants Experiencing Laboratory Abnormalities in Selected Liver Parameters

The number of participants experiencing laboratory abnormalities in the specific pre-determined liver tests.

Time frame:
From first dose up to 30 days post last dose of the blinded phase (up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Laboratory Abnormalities in Selected Liver Parameters
ParticipantsNivolumabPlacebo
ALT OR AST > 3XULN295
ALT OR AST > 5XULN162
ALT OR AST > 10XULN60
ALT OR AST > 20XULN20
TOTAL BILIRUBIN > 2XULN35
ALP > 1.5XULN201
SecondaryOverall Survival (OS)

OS is defined as the time between the date of randomization and the date of death. For those without documentation of death, OS will be censored on the last date the participant was known to be alive.

Time frame:
From randomization up to the date of death or the last date the participant was known to be alive

Results for this outcome have not been posted.

Adverse events

Collected over Participants were assessed for all-cause mortality from their randomization to primary completion, (up to approximately 32 months). SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 32 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab14/526 (2.7%)95/524 (18.1%)464/524 (88.5%)
Placebo8/264 (3%)37/264 (14%)194/264 (73.5%)
Open-Label Nivolumab2/32 (6.3%)5/30 (16.7%)20/30 (66.7%)
Most frequent serious events
Showing 10 of 134
Most frequent serious events
EventNivolumabPlaceboOpen-Label Nivolumab
Alanine aminotransferase increasedInvestigations4/5240/2642/30
ColitisGastrointestinal disorders4/5241/2641/30
Hiatus herniaGastrointestinal disorders0/5241/2641/30
VolvulusGastrointestinal disorders0/5240/2641/30
General physical health deteriorationGeneral disorders0/5240/2641/30
PneumoniaInfections and infestations2/5240/2641/30
Aspartate aminotransferase increasedInvestigations4/5241/2641/30
Muscular weaknessMusculoskeletal and connective tissue disorders0/5240/2641/30
Acute kidney injuryRenal and urinary disorders3/5241/2641/30
UrticariaSkin and subcutaneous tissue disorders0/5241/2641/30
Most frequent other events
Showing 10 of 37
Most frequent other events
EventNivolumabPlaceboOpen-Label Nivolumab
FatigueGeneral disorders140/52467/2646/30
DiarrhoeaGastrointestinal disorders121/52444/2643/30
PruritusSkin and subcutaneous tissue disorders107/52429/2643/30
ArthralgiaMusculoskeletal and connective tissue disorders87/52431/2643/30
NauseaGastrointestinal disorders78/52430/2641/30
Dry mouthGastrointestinal disorders41/52410/2644/30
AstheniaGeneral disorders63/52425/2644/30
PyrexiaGeneral disorders35/52413/2644/30
COVID-19Infections and infestations46/52423/2644/30
RashSkin and subcutaneous tissue disorders69/52426/2642/30

Baseline characteristics

Age, Continuous
Age, Continuous(Years)NivolumabPlaceboTotal
Mean59.9 ± 13.959.3 ± 13.659.7 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)NivolumabPlaceboTotal
Female204103307
Male322161483
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NivolumabPlaceboTotal
Hispanic or Latino11617
Not Hispanic or Latino317140457
Unknown or Not Reported198118316
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NivolumabPlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American213
White515262777
More than one race000
Unknown or Not Reported819
08

Study locations

130 sites
  • Local Institution - 0088
    Birmingham, Alabama 35294-3300, United States
  • Local Institution - 0126
    Tucson, Arizona 85724-5024, United States
  • Local Institution - 0087
    Springdale, Arkansas 72762, United States
  • Local Institution - 0080
    Los Angeles, California 90025, United States
  • Local Institution - 0077
    San Francisco, California 94115, United States
  • Local Institution - 0119
    San Francisco, California 94115, United States
  • Local Institution - 0122
    San Jose, California 95119, United States
  • Local Institution - 0121
    Vallejo, California 94589-2441, United States
  • Local Institution - 0109
    Vallejo, California 94589, United States
  • Local Institution - 0120
    Vallejo, California 94589, United States
  • Local Institution - 0091
    Aurora, Colorado 80045, United States
  • Local Institution - 0089
    Washington D.C., District of Columbia 20057, United States
  • Local Institution - 0141
    Atlanta, Georgia 30342, United States
  • Local Institution - 0132
    Chicago, Illinois 60611, United States
  • Local Institution - 0135
    Baltimore, Maryland 21237, United States
  • Local Institution - 0078
    Boston, Massachusetts 02215, United States
  • Local Institution - 0127
    Boston, Massachusetts 02215, United States
  • Local Institution - 0143
    Boston, Massachusetts 02215, United States
  • Local Institution - 0151
    Minneapolis, Minnesota 55407, United States
  • Local Institution - 0081
    Robbinsdale, Minnesota 55407, United States
  • Local Institution - 0079
    Omaha, Nebraska 68130, United States
  • Local Institution - 0093
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0094
    New York, New York 10016, United States
  • Local Institution - 0086
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0099
    Cleveland, Ohio 44195, United States
  • Local Institution - 0076
    Portland, Oregon 97213, United States
  • Local Institution - 0092
    Allentown, Pennsylvania 18103, United States
  • Local Institution - 0031
    Pittsburgh, Pennsylvania 15232, United States
  • Local Institution - 0148
    Germantown, Tennessee 38138, United States
  • Local Institution - 0144
    Austin, Texas 78731, United States
  • Local Institution - 0085
    Dallas, Texas 75246, United States
  • Local Institution - 0090
    Fairfax, Virginia 22031, United States
  • Local Institution - 0018
    Waratah, New South Wales 2298, Australia
  • Local Institution - 0025
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0016
    Wollstonecraft, New South Wales 2065, Australia
  • Local Institution - 0105
    Cairns, Queensland 4870, Australia
  • Local Institution - 0017
    Greenslopes, Queensland 4120, Australia
  • Local Institution - 0024
    Herston, Queensland 4029, Australia
  • Local Institution - 0138
    Southport, Queensland 4120, Australia
  • Local Institution - 0019
    Box Hill, Victoria 3128, Australia
  • Local Institution - 0125
    Geelong, Victoria 3220, Australia
  • Local Institution - 0128
    Malvern, Victoria 3144, Australia
  • Local Institution - 0106
    Melbourne, Victoria 3004, Australia
  • Local Institution - 0104
    Nedlands, Western Australia 6009, Australia
  • Local Institution - 0049
    Graz, 8036, Austria
  • Local Institution - 0051
    Innsbruck, 6020, Austria
  • Local Institution - 0050
    Salzburg, 5020, Austria
  • Local Institution - 0048
    Vienna, 1090, Austria
  • Local Institution - 0028
    Charleroi, 6000, Belgium
  • Local Institution - 0011
    Ghent, 9000, Belgium
  • Local Institution - 0008
    Kortrijk, 8500, Belgium
  • Local Institution - 0010
    Liège, 4000, Belgium
  • Local Institution - 0134
    Calgary, Alberta T2N 4N2, Canada
  • Local Institution - 0133
    Vancouver, British Columbia V5Z 4E6, Canada
  • Local Institution - 0131
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Local Institution - 0142
    Hamilton, Ontario L8V 5C2, Canada
  • Local Institution - 0124
    Kingston, Ontario K7L 2V7, Canada
  • Local Institution - 0140
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0116
    Montreal, Quebec H2X 3E4, Canada
  • Local Institution - 0123
    Sherbrooke, Quebec J1H 5N4, Canada
  • Local Institution - 0074
    Prague, Praha 2 12808, Czechia
  • Local Institution - 0075
    Ostrava-Poruba, 708 52, Czechia
  • Local Institution - 0073
    Prague, 100 34, Czechia
  • Local Institution - 0007
    Aarhus N, 8200, Denmark
  • Local Institution - 0012
    Herlev, 2730, Denmark
  • Local Institution - 0013
    Odense, 5000, Denmark
  • Local Institution - 0014
    Helsinki, Etelä-Suomen Lääni 00290, Finland
  • Local Institution - 0015
    Tampere, Pirkanmaa 33520, Finland
  • Local Institution - 0110
    Turku, 20251, Finland
  • Local Institution - 0113
    Brest, Finistère 29200, France
  • Local Institution - 0129
    Besançon, 25030, France
  • Local Institution - 0112
    Bordeaux, 33075, France
  • Local Institution - 0111
    Lille, 59037, France
  • Local Institution - 0033
    Marseille, 13011, France
  • Local Institution - 0035
    Nantes, 44000, France
  • Local Institution - 0130
    Nice, 06200, France
  • Local Institution - 0036
    Paris, 75475, France
  • Local Institution - 0032
    Pierre-Bénite, 69495, France
  • Local Institution - 0034
    Villejuif, 94800, France
  • Local Institution - 0056
    München, Bavaria 81377, Germany
  • Local Institution - 0072
    Bonn, 53127, Germany
  • Local Institution - 0061
    Buxtehude, 21614, Germany
  • Local Institution - 0098
    Dresden, 01307, Germany
  • Local Institution - 0054
    Essen, 45122, Germany
  • Local Institution - 0062
    Gera, 07548, Germany
  • Local Institution - 0114
    Göttingen, 37075, Germany
  • Local Institution - 0060
    Hanover, 30625, Germany
  • Local Institution - 0055
    Heidelberg, 69120, Germany
  • Local Institution - 0057
    Lübeck, 23538, Germany
  • Local Institution - 0100
    Mainz, 55131, Germany
  • Local Institution - 0102
    Regensburg, 93053, Germany
  • Local Institution - 0058
    Tübingen, 72076, Germany
  • Local Institution - 0084
    Athens, Attikí 185 47, Greece
  • Local Institution - 0082
    Athens, 115 27, Greece
  • Local Institution - 0083
    Thessaloniki, 57100, Greece
  • Local Institution - 0046
    Palermo, Sicily 90127, Italy
  • Local Institution - 0040
    Bergamo, 24127, Italy
  • Local Institution - 0037
    Milan, 20133, Italy
  • Local Institution - 0146
    Milan, 20141, Italy
  • Local Institution - 0101
    Naples, 80131, Italy

Showing the first 100 of 130 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kirkwood JM, Mohr P, Hoeller C, Grob JJ, Del Vecchio M, Lord-Bessen J, Srinivasan S, Nassar A, Campigotto F, Fairbanks H, Taylor F, Lawrance R, Long GV, Weber J. Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial. Eur J Cancer. 2025 May 2;220:115371. doi: 10.1016/j.ejca.2025.115371. Epub 2025 Mar 19. PubMed 40139004 ↗
  • Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023 Nov;29(11):2835-2843. doi: 10.1038/s41591-023-02583-2. Epub 2023 Oct 16. PubMed 37845511 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Jun 2022, 32 months.

Results were first posted in Jul 2023, 1 year after primary completion.

Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 32 months is below that.

Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2019
First posted
Sep 23, 2019
StartActual
Oct 28, 2019
Primary completionActual
Jun 28, 2022
CompletionEst.
Nov 30, 2026
Results first posted
Jul 27, 2023
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04099251
Responsible party
Sponsor
First posted
Sep 23, 2019
Start date
Oct 28, 2019
Primary completion
Jun 28, 2022
Completion
Nov 30, 2026 (estimated)
Results posted
Jul 27, 2023
Last update
Aug 7, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion